|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.48 EUR | +1.47% |
|
+4.70% | -7.54% |
| 07-09 | Novo Nordisk launches weekly insulin shot Awiqli in India | RE |
| 07-08 | European Stocks Close Sharply Lower in Wednesday Trading; Oil Prices Spike as US-Iran War Reignites | MT |
Company Valuation: Sanofi
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 111,194 | 112,665 | 112,549 | 116,968 | 100,655 | 91,793 | - | - |
| Change | - | 1.32% | -0.1% | 3.93% | -13.95% | -8.8% | - | - |
| Enterprise Value (EV) 1 | 121,177 | 119,102 | 120,342 | 125,740 | 111,663 | 101,424 | 97,312 | 93,912 |
| Change | - | -1.71% | 1.04% | 4.49% | -11.2% | -9.17% | -4.05% | -3.49% |
| P/E | 17.8x | 16.7x | 20.8x | 20.4x | 12.9x | 11.5x | 10.6x | 9x |
| PBR | 1.62x | 1.5x | 1.52x | 1.51x | 1.41x | 1.22x | 1.17x | 1.1x |
| PEG | - | 2.07x | -1.1x | 3.14x | 0.3x | 3.25x | 1.19x | 0.5x |
| Capitalization / Revenue | 2.94x | 2.62x | 2.61x | 2.85x | 2.31x | 1.94x | 1.83x | 1.73x |
| EV / Revenue | 3.21x | 2.77x | 2.79x | 3.06x | 2.56x | 2.15x | 1.94x | 1.77x |
| EV / EBITDA | 9.95x | 8.14x | 8.44x | 9.76x | 8.22x | 6.93x | 6.23x | 5.5x |
| EV / EBIT | 11.3x | 9.13x | 9.5x | 11.1x | 9.19x | 7.9x | 7.08x | 6.24x |
| EV / FCF | 15x | 14x | 14.2x | 21.1x | 13.8x | 11.8x | 10.7x | 9.2x |
| FCF Yield | 6.68% | 7.12% | 7.04% | 4.74% | 7.24% | 8.46% | 9.36% | 10.9% |
| Dividend per Share 2 | 3.33 | 3.56 | 3.76 | 3.92 | 4.12 | 4.254 | 4.506 | 4.831 |
| Rate of return | 3.76% | 3.96% | 4.19% | 4.18% | 4.98% | 5.56% | 5.89% | 6.32% |
| EPS 2 | 4.97 | 5.37 | 4.31 | 4.59 | 6.4 | 6.626 | 7.214 | 8.497 |
| Distribution rate | 67% | 66.3% | 87.2% | 85.4% | 64.4% | 64.2% | 62.5% | 56.9% |
| Net sales 1 | 37,761 | 42,997 | 43,070 | 41,081 | 43,626 | 47,197 | 50,266 | 52,909 |
| EBITDA 1 | 12,183 | 14,627 | 14,259 | 12,889 | 13,583 | 14,630 | 15,608 | 17,090 |
| EBIT 1 | 10,714 | 13,040 | 12,670 | 11,343 | 12,149 | 12,837 | 13,748 | 15,055 |
| Net income 1 | 6,223 | 6,720 | 5,400 | 5,744 | 7,813 | 7,990 | 8,903 | 10,549 |
| Net Debt 1 | 9,983 | 6,437 | 7,793 | 8,772 | 11,008 | 9,631 | 5,519 | 2,119 |
| Reference price 2 | 88.58 | 89.84 | 89.76 | 93.74 | 82.72 | 76.48 | 76.48 | 76.48 |
| Nbr of stocks (in thousands) | 1,255,293 | 1,254,060 | 1,253,891 | 1,247,793 | 1,216,810 | 1,200,220 | - | - |
| Announcement Date | 04/02/22 | 03/02/23 | 01/02/24 | 30/01/25 | 29/01/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 11.37x | 2.12x | 6.85x | 5.64% | 103B | ||
| 35.46x | 12.91x | 26.29x | 0.56% | 1,084B | ||
| 28.11x | 6.45x | 17.52x | 2.03% | 634B | ||
| 30.45x | 7.46x | 15.28x | 2.72% | 447B | ||
| 17.81x | 4.43x | 10.97x | 2.99% | 330B | ||
| 23.78x | 4.98x | 13.89x | 1.75% | 295B | ||
| 21.66x | 5.57x | 13.46x | 2.83% | 285B | ||
| 14.26x | 5.31x | 10.9x | 3.51% | 218B | ||
| 24.07x | 6.37x | 11.22x | 2.74% | 199B | ||
| -48.15x | 5.84x | 32.48x | 2.39% | 169B | ||
| Average | 15.88x | 6.14x | 15.88x | 2.72% | 376.3B | |
| Weighted average by Cap. | 23.88x | 7.86x | 18.27x | 2.05% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SAN Stock
- Valuation Sanofi
Select your edition
All financial news and data tailored to specific country editions
















